| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-306 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2017-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-WO2018088403-A1 |
| titleOfInvention |
Fragment antibody and protein crystallization method using the fragment antibody |
| abstract |
The present invention can be easily produced as having antigen-binding activity, and even if it is obtained in an E. coli expression system, the complex of itself and an antigen molecule rather than Fv-class (v1). PROBLEM TO BE SOLVED To provide a fragment antibody having high crystallization ability The present invention is a peptide in which the N-terminus of the SARAH domain is bound to the C-terminus of the heavy chain domain (VH region) of the antibody, and the VH region is determined by the Chothia method. A peptide in which the amino acid residue of antibody residue number 112 is mutated to cysteine (VH (112C) -SARAH), and a peptide in which the N-terminus of the SARAH domain is bound to the C-terminus of the light chain domain (VL region) of the antibody. Thus, a peptide (VL-SARA (3 It relates to a fragment antibody comprising a complex with 7C)). |
| priorityDate |
2016-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |